We develop hardware for gene delivery. Our focus is on gene-modified cell therapy production. Gene-modified cell therapies are important because these therapies are the most effective platform for patients with late-stage and advanced disease. Nobody, however, knows how to reliably produce gene-modified cell therapies at scale.

 

supported by